Care Modules

RENAL
DIABETES
CARDIAC
BEHAVIORAL
RESPIRATORY

Renal Disease

Chronic kidney disease and end-stage

$32 billion ANNUAL ECONOMIC BURDEN

The American Society of Nephrology (ASN) states that the annual economic burden of ESRD is $32 billion

Affects 37 million adults

About 37 million U.S. adults are estimated to have CKD, and most are undiagnosed – IQVIA

40% suffer without diagnosis

40% of people with severely reduced kidney function are not aware of having CKD – IQVIA

According to the CDC, 9 out of 10 adults with CKD do not know they have CKD.

USC Center for Health Policy and Economics states, “patients with ESKD have average monthly spending 33× higher than patients without.

Early Disease burden

Overall health care costs ranged from $26,889 (A1) to $42,139 (A3), and from $28,627 (G2) to $42,902 (G5) per patient per year, demonstrating a considerable early disease burden which continued to increase with declining kidney function. KIREREPORTS Kidney International Reports - February 3, 2023

HIGH PPPY COSTS with commercial payers

The PPPY costs of later stage CKD were particularly notable for patients with concomitant heart failure ($50,191) and those covered by commercial payers ($55,735). KIREREPORTS Kidney International Reports - February 3, 2023

33x higher monthly spending

USC Center for Health Policy and Economics states, “Patients with ESKD have average monthly spending 33× higher than patients without."

"We're looking forward to advancing our AI initiatives to provide a higher level of precision and improve our customers' insights into their own data"

Paul F. Beyer

CEO, Ascend

Halt Progression, Reduce Costs.

DeLorean AI's state-of-the-art, pre-trained Renal AI solution identifies individual patients with undiagnosed renal conditions and precisely predicts which patients are on the verge of progressing to CKD and End-State Renal Disease. Physicians supported with Renal AI can precisely identify and effectively intervene with patients in order to halt disease progression and drastically lower overall patient care costs.

Halt progression to CKD and End-State

Identify patients with undiagnosed renal conditions

Lower patient care costs

Enhance nurse and technician performance

Improve patient quality of life

Diabetes

Undiagnosed diabetes, pre-diabetes, diabetes, and type 2 diabetes

38.4 million people have diabetes

38.4 million people have diabetes (11.6% of the US population) – CDC

increasing medical costs

The direct medical costs attributed to diabetes increased by 7% between 2017 and 2022

Nearly $413 Billion in Costs Annually

Annual Costs of Diabetes is currently $412.9 Billion including $306.6 billion in direct medical costs and $106.3 billion in indirect costs - American Diabetes Association November 1, 2023

Millions are undiagnosed

8.7 million adults aged 18 years or older who met laboratory criteria for diabetes were not aware of or did not report having diabetes (undiagnosed diabetes). This number represents 3.4% of all US adults and 22.8% of all US adults with diabetes. - CDC

2.6x Medical expenditures with diabetes

On average, people with diagnosed diabetes have medical expenditures 2.6 time higher than would be expected without diabetes – ADA

INSULIN SPENDING HAS TRIPLED

Spending on insulin tripled in the past 10 years- increasing from $8 billion in 2012 to $22.3 billion in 2022. - ADA

POPULATION GROWING EXPONENTIALLY

By 2060, the diabetes population in the U.S. is expected to double to over 60 million patients, with up to 40% also suffering from CKD, many of whom will remain undiagnosed. IQVIA

Prevention through early prediction

You can prevent or delay prediabetes from turning into type 2 diabetes with simple, proven lifestyle changes. – CDC

Lifestyle changes make a difference

Successful lifestyle changes reduce medication needs for high blood pressure and high cholesterol, and avoid the psychosocial stress associated with developing type 2 diabetes. - NIH

The benefits of screening

The USPSTF concludes that screening for prediabetes and type 2 diabetes and offering or referring patients with prediabetes to effective preventive interventions has a moderate net benefit.

INCREASED TREATMENT COSTS

For patients under the age of 65 with both CKD and T2D, the cost of treatment can be as much as 60% higher than treating T2D alone.

Prevention is possible

Our advanced, pre-trained Diabetes AI platform pinpoints members who have yet to be diagnosed with diabetic ailments, while also accurately forecasting those at imminent risk of advancing from Prediabetes to Type 2. Physicians equipped with our Diabetes AI are empowered to detect at-risk patients with greater precision and intervene effectively, thereby arresting the progression of the disease and significantly reducing the cost of patient care.

Prevent transition to type 2

Identify and treat patients with undiagnosed diabetic conditions

Lower patient care costs

Provide hyper-personalized care

Improve patient quality of life

Enhance nurse and technician performance

Risk CLASSIFICATION OF DISEASE ONSET & PROGRESSION

Diabetes AI makes use of the entire patient population, instead of samples, to ensure sub-populations are captured and comprehensive risk classifications can be assigned to adeptly identify those who are at-risk

HYPER-PERSONALIZED PATIENT VIEW

With the entire population modeled, Diabetes AI can monitor each patient on an individual level and create specific, tailored recommendations for treatment protocols and appropriately provide interventive measures when needed

PREDICT CHANGES IN HEALTH AND TREATMENT

Diabetes AI generates predictions in real-time, as new data enters the environment, monitoring those who are at-risk for developing diseases, transitioning to a worse disease state, or evaluating treatment for patients based on the stage / severity of the disease

NEXT-BEST-ACTION RECOMMENDATIONS TO OPTIMIZE CARE

When differences are detected between predictions and actions, Diabetes AI will make a next-best- action recommendation for the healthcare professional to review and act upon

CARDIAC Disease

Hypertension, ischemic artery disease and heart failure

AFFECTS 119.9 million AMERICANS

Nearly half of adults have hypertension (119.9 million) – MillionHearts

$2000 higher annual spending

Individuals with hypertension are estimated to face nearly $2000 higher annual healthcare expenditure compared with their nonhypertensive peers. - AHA

$131 Billion in Healthcare Costs

Healthcare costs associated with hypertension account for about $131 billion. – AHA

Costs the United States $239.9 Billion a year

Heart disease cost the United States about $239.9 billion each year from 2018 to 2019. This includes the cost of health care services, medicines, and lost productivity due to death. – CDC

a compounding issue

By 2035, nearly half of the U.S. population will have some form of cardiovascular disease. – AHA

$1.1 Trillion projected costs by 2035

The projected costs by 2035 of CVD are $1.1 trillion. – AHA

Identify and Intervene

Leveraging our pre-trained Cardiac AI, we are able to uncover individual cases of undiagnosed heart conditions and accurately determine who is at risk of progressing to more severe stages. This provides clinical teams with the critical ability to identify and proactively address the needs of these patients, preventing disease progression and significantly decreasing the associated healthcare expenses.

Identify patients with undiagnosed hypertension and Ischemic Artery Disease

Predict episodic cardiac events

Lower patient care costs

Provide hyper-personalized care

Improve patient quality of life

Enhance nurse and technician performance

Behavior Health

Major depressive disorders including Mild, Moderate, severe and Psychotic

AFFECTS 45.3 million AMERICANS

Mental illness affects 23% (45.3 million) of non-elderly adults, with 11% having mild conditions, 6% moderate, and 6% severe conditions. - KFF

associated with higher spending

Having a mental health disorder was associated with substantially higher spending on for other medical conditions, which increased total spending associated with mental health disorders 3-fold. JAMA

HYPER-PERSONALIZED PATIENT VIEW

With the entire population modeled, Behavioral Health AI can monitor each patient on an individual level and create specific, tailored recommendations for treatment protocols and appropriately provide interventive measures when needed

Identify Undiagnosed Patients

DeLorean AI's state-of-the-art, pre-trained Behavioral Health AI identifies individual patients with undiagnosed behavioral health issues. Clinical teams supported with Behavioral AI can precisely identify and effectively intervene with patients in order to halt disease progression and drastically lower overall patient care costs.

Halt progression to advanced disease stages

Lower patient care costs

Improve patient quality of life

Enhance nurse and technician performance

Respiratory Disease

COPD, Emphysema and chronic bronchitis

--- Coming q1 of 2024 ---

Economic Costs of $50 Billion a Year

The total economic cost of COPD is close to $50 billion each year, including $29.5 billion for direct health care expenditures, $12.4 billion for indirect mortality costs, and $8.0 billion for indirect morbidity costs.

Annual Costs up 52.6%

Costs linked to COPD in the U.S. shot up to $49.0 billion in 2020, from $32.1 billion in 2010 -- a 52.6% jump, according to the CDC.

$6000+ higher annual spending

On an individual level, a 2018 study estimated an average person with COPD racked up $6,246 more per year in direct medical costs than other people.

Treatment yields savings

For patients receiving treatment, i.e. Integrated Care Pathway care, 30-day readmissions declined by 57%, and 90-day all-cause hospitalizations declined by 36%. Calculated total direct cost savings per patient per year (PPPY) for the hospital were $29,044 and $21,470 for years one and five, respectively. – NIH

Intervention with Precision

Utilizing our advanced RespiratoryAI, which has been meticulously trained, we are equipped to detect respiratory conditions that have not been previously diagnosed. RespiratoryAI precisely pinpoints individuals who are at an increased risk of developing more serious health issues. This pivotal tool empowers medical teams to proactively intervene, offering necessary care to patients early on. By doing so, it halts the progression of the disease and substantially cuts down on medical costs.

Spotting patients who have not yet been diagnosed with COPD

Reducing the expenses related to patient care

Providing care that is exceptionally tailored to the individual needs of each patient

Elevating the overall quality of life for patients

Boosting the efficiency and effectiveness of nurses and technicians

:
Back to top